You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: September 24, 2023

XOFIGO Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Xofigo patents expire, and what generic alternatives are available?

Xofigo is a drug marketed by Bayer Hlthcare and is included in one NDA.

The generic ingredient in XOFIGO is radium ra-223 dichloride. One supplier is listed for this compound. Additional details are available on the radium ra-223 dichloride profile page.

Summary for XOFIGO
US Patents:0
Finished Product Suppliers / Packagers: 1
Clinical Trials: 30
Drug Prices: Drug price information for XOFIGO
What excipients (inactive ingredients) are in XOFIGO?XOFIGO excipients list
DailyMed Link:XOFIGO at DailyMed
Drug patent expirations by year for XOFIGO
Drug Prices for XOFIGO

See drug prices for XOFIGO

Recent Clinical Trials for XOFIGO

Identify potential brand extensions & 505(b)(2) entrants

GenesisCare USAPhase 3
BayerPhase 4

See all XOFIGO clinical trials

US Patents and Regulatory Information for XOFIGO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare XOFIGO radium ra-223 dichloride SOLUTION;INTRAVENOUS 203971-001 May 15, 2013 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for XOFIGO

See the table below for patents covering XOFIGO around the world.

Country Patent Number Title Estimated Expiration
Turkey 200102707 ⤷  Try a Trial
New Zealand 534618 The preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning ⤷  Try a Trial
New Zealand 545023 Preparation comprising dissolved radium-223 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for XOFIGO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1140212 2014/033 Ireland ⤷  Try a Trial PRODUCT NAME: RADIUM-223 AND SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/873 20131113
1140212 33/2014 Austria ⤷  Try a Trial PRODUCT NAME: RADIUM-223-DICHLORID; REGISTRATION NO/DATE: EU/1/13/873 20131113
1140212 CA 2014 00027 Denmark ⤷  Try a Trial PRODUCT NAME: RADIUM-223 OG OPLOESELIGE SALTE DERAF, HERUNDER RADIUM-223 DICHLORID; REG. NO/DATE: EU/1/13/873 20131113
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.